Unique ID issued by UMIN | UMIN000027632 |
---|---|
Receipt number | R000031633 |
Scientific Title | A feasibility study of perioperative administration of immunoenhancing enteral nutrients combined with pancrelipase in patients with pancreatoduodenectomy for pancreatic cancer |
Date of disclosure of the study information | 2017/07/01 |
Last modified on | 2018/01/31 22:34:52 |
A feasibility study of perioperative administration of immunoenhancing enteral nutrients combined with pancrelipase in patients with pancreatoduodenectomy for pancreatic cancer
A feasibility study of perioperative administration of immunoenhancing enteral nutrients combined with pancrelipase in patients with pancreatoduodenectomy for pancreatic cancer
A feasibility study of perioperative administration of immunoenhancing enteral nutrients combined with pancrelipase in patients with pancreatoduodenectomy for pancreatic cancer
A feasibility study of perioperative administration of immunoenhancing enteral nutrients combined with pancrelipase in patients with pancreatoduodenectomy for pancreatic cancer
Japan |
Pancreatic cancer
Hepato-biliary-pancreatic surgery |
Malignancy
NO
To investigate the improvement of nutritional status and reduction of postoperative complications by ingestion of immunoenhancing enteral nutrients and pancrelipase in patients undergoing pancreaticoduodenectomy
Safety,Efficacy
Treatment completion rate of preoperative ingestion of immunoenhancing enteral nutrients and pancrelipase
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Food |
1, Administration of immune-enhancing enteral nutrients from 2 weeks before surgery to 3 weeks after surgery. The dose of nutrients depends on the phase from 480kcal to 960kcal,
2. Administration of pancrelipase from postoperative day 1 to 21. The dose of pancrelipase is 1800mg per day.
20 | years-old | <= |
Not applicable |
Male and Female
1. Patients diagnosed with pancreatic cancer
2. Patients who will undergo Pancreaticoduodenectomy
3. ECOG-PS 0 or 1
4. Patients who can intake orally
5. Patients who fully understand the study procedures and consent the document voluntary after an adequate explanation
1. Patients with active double cancer
2. Patients who have active infection
3. Patients who need to restrict food or water intake
4. Patients with milk or soy allergy
5. Patients with pancrelipase allergy
6. Patients with pork protein allergy
7. Patients with ileus
8. Patients with advanced liver dysfunction or advanced renal dysfunction
9. Patients with abnormal glucose metabolism, such as severe diabetes
10. Patients with congenital disorders of amino acid metabolism
11. Patients with pregnancy
12. Patients who were deemed inappropriate for medical reasons
20
1st name | |
Middle name | |
Last name | Yasuhiro Kodera |
Nagoya University, Graduate School of Medicine
Gastroenterorogical Surgery
65 Tsurumai-cho Showa-ku Nagoya city
052-744-2253
ykodera@med.nagoya-u.ac.jp
1st name | |
Middle name | |
Last name | Suguru Yamada |
Nagoya University, Graduate School of Medicine
Gastroenterorogical Surgery
65 Tsurumai-cho Showa-ku Nagoya city
052-744-2253
suguru@med.nagoya-u.ac.jp
Nagoya University, Graduate School of Medicine
Nagoya University, Graduate School of Medicine
Other
NO
2017 | Year | 07 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2017 | Year | 06 | Month | 01 | Day |
2017 | Year | 07 | Month | 01 | Day |
2017 | Year | 06 | Month | 04 | Day |
2018 | Year | 01 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031633